Skip to main content
Top
Published in: Current Cardiology Reports 7/2023

Open Access 17-06-2023 | Iron Deficiency | Myocardial Disease (A Abbate and M Merlo, Section Editors)

Treatment of Iron Deficiency in Heart Failure

Authors: Aamir Shamsi, Antonio Cannata, Susan Piper, Daniel I. Bromage, Theresa A. McDonagh

Published in: Current Cardiology Reports | Issue 7/2023

Login to get access

Abstract

Purpose of Review

Heart failure (HF) is commonly associated with iron deficiency (ID), defined as insufficient levels of iron to meet physiological demands. ID’s association with anaemia is well understood but it is increasingly recognised as an important comorbidity in HF, even in the absence of anaemia. This review summarises contemporary evidence for the measurement and treatment of ID, in both HFrEF and HFpEF, and specific HF aetiologies, and highlights important gaps in the evidence-base.

Recent Findings

ID is common among patients with HF and associated with increased morbidity and mortality. Correcting ID in patients with HF can impact upon functional status, exercise tolerance, symptoms, and overall quality of life, irrespective of anaemia status.

Summary

ID is a modifiable comorbidity in HF. Therefore, recognising and treating ID has emerging therapeutic potential and is important for all clinicians who care for patients with HF to understand the rationale and approach to treatment.
Literature
10.
go back to reference Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med [Internet]. 2009 [cited 2022 Jul 3];361(25):2436–48. Available from:https://doi.org/10.1056/nejmoa0908355. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med [Internet]. 2009 [cited 2022 Jul 3];361(25):2436–48. Available from:https://​doi.​org/​10.​1056/​nejmoa0908355.
11.
go back to reference Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleśkowska-Florek W, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J [Internet]. 2014 [cited 2022 Jul 3];35(36):2468–76. Available from: https://pubmed.ncbi.nlm.nih.gov/24927731/. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleśkowska-Florek W, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J [Internet]. 2014 [cited 2022 Jul 3];35(36):2468–76. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​24927731/​.
12.
15.
go back to reference Sierpinski R, Josiak K, Suchocki T, Wojtas-Polc K, Mazur G, Butrym A, et al. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail [Internet]. 2021 [cited 2022 Jul 12];23(6):919–32. Available from: https://pubmed.ncbi.nlm.nih.gov/33111457/. Sierpinski R, Josiak K, Suchocki T, Wojtas-Polc K, Mazur G, Butrym A, et al. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail [Internet]. 2021 [cited 2022 Jul 12];23(6):919–32. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​33111457/​.
17.
18.
go back to reference McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J [Internet]. 2021 [cited 2022 Jul 12];42(36):3599–726. Available from: https://academic.oup.com/eurheartj/article/42/36/3599/6358045. Accessed 25 Oct 2022. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J [Internet]. 2021 [cited 2022 Jul 12];42(36):3599–726. Available from: https://​academic.​oup.​com/​eurheartj/​article/​42/​36/​3599/​6358045. Accessed 25 Oct 2022.
19.
go back to reference Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron Deficiency in Community-Dwelling U.S. Adults with self-reported heart failure in NHANES III: prevalence and associations with anemia and inflammation. Circ Heart Fail [Internet]. 2011 [cited 2022 Jul 3];4(5):599. Available from: https://pubmed.ncbi.nlm.nih.gov/21705484/. Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron Deficiency in Community-Dwelling U.S. Adults with self-reported heart failure in NHANES III: prevalence and associations with anemia and inflammation. Circ Heart Fail [Internet]. 2011 [cited 2022 Jul 3];4(5):599. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​21705484/​.
21.
24.
go back to reference Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2012 [cited 2022 Jul 19];23(8):1954–62. Available from: https://pubmed.ncbi.nlm.nih.gov/22575608/. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2012 [cited 2022 Jul 19];23(8):1954–62. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​22575608/​.
33.
34.
go back to reference Aung N, Ling HZ, Cheng AS, Aggarwal S, Flint J, Mendonca M, et al. Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. Int J Cardiol [Internet]. 2013 [cited 2022 Jul 5];168(3):1997–2002. Available from: https://pubmed.ncbi.nlm.nih.gov/23351789/. Aung N, Ling HZ, Cheng AS, Aggarwal S, Flint J, Mendonca M, et al. Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. Int J Cardiol [Internet]. 2013 [cited 2022 Jul 5];168(3):1997–2002. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​23351789/​.
35.
go back to reference Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol [Internet]. 2011 [cited 2022 Jul 5];58(12):1241–51. Available from: https://pubmed.ncbi.nlm.nih.gov/21903058/. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol [Internet]. 2011 [cited 2022 Jul 5];58(12):1241–51. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​21903058/​.
36.
go back to reference Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail [Internet]. 2011 [cited 2022 Jul 6];17(11):899–906. Available from: https://pubmed.ncbi.nlm.nih.gov/22041326/. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail [Internet]. 2011 [cited 2022 Jul 6];17(11):899–906. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​22041326/​.
37.
go back to reference Comín-Colet J, Enjuanes C, González G, Torrens A, Cladellas M, Meroño O, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail [Internet]. 2013 [cited 2022 Jul 6];15(10):1164–72. Available from: https://pubmed.ncbi.nlm.nih.gov/23703106/. Comín-Colet J, Enjuanes C, González G, Torrens A, Cladellas M, Meroño O, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail [Internet]. 2013 [cited 2022 Jul 6];15(10):1164–72. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​23703106/​.
38.
go back to reference Yeo TJ, Yeo PSD, Ching-Chiew Wong R, Ong HY, Leong KTG, Jaufeerally F, et al. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail [Internet]. 2014 [cited 2022 Oct 16];16(10):1125–32. Available from: https://pubmed.ncbi.nlm.nih.gov/25208495/. Yeo TJ, Yeo PSD, Ching-Chiew Wong R, Ong HY, Leong KTG, Jaufeerally F, et al. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail [Internet]. 2014 [cited 2022 Oct 16];16(10):1125–32. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​25208495/​.
39.
go back to reference Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol [Internet]. 2014 [cited 2022 Jul 6];174(2):268–75. Available from: https://pubmed.ncbi.nlm.nih.gov/24768464/. Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol [Internet]. 2014 [cited 2022 Jul 6];174(2):268–75. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​24768464/​.
40.
go back to reference Kasner M, Aleksandrov AS, Westermann D, Lassner D, Gross M, Von Haehling S, et al. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. Int J Cardiol [Internet]. 2013 [cited 2022 Jul 6];168(5):4652–7. Available from: https://pubmed.ncbi.nlm.nih.gov/23968714/. Kasner M, Aleksandrov AS, Westermann D, Lassner D, Gross M, Von Haehling S, et al. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. Int J Cardiol [Internet]. 2013 [cited 2022 Jul 6];168(5):4652–7. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​23968714/​.
41.
go back to reference Alcaide-Aldeano A, Garay A, Alcoberro L, Jiménez-Marrero S, Yun S, Tajes M, et al. Iron deficiency: impact on functional capacity and quality of life in heart failure with preserved ejection fraction. J Clin Med [Internet]. 2020 [cited 2022 Jul 24];9(4):1199. Available from: https://pubmed.ncbi.nlm.nih.gov/32331365/. Alcaide-Aldeano A, Garay A, Alcoberro L, Jiménez-Marrero S, Yun S, Tajes M, et al. Iron deficiency: impact on functional capacity and quality of life in heart failure with preserved ejection fraction. J Clin Med [Internet]. 2020 [cited 2022 Jul 24];9(4):1199. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​32331365/​.
44.
go back to reference Toblli JE, Cao G, Olivieri L, Angerosa M. Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats. Pharmacology [Internet]. 2008 Aug [cited 2022 Jul 11];82(2):127–37. Available from: https://pubmed.ncbi.nlm.nih.gov/18607114/. Toblli JE, Cao G, Olivieri L, Angerosa M. Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats. Pharmacology [Internet]. 2008 Aug [cited 2022 Jul 11];82(2):127–37. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​18607114/​.
46.
go back to reference Crichton RR, Danielson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. UNI-MED-Verlag, 2005. Bremen, Germany; 2008. Crichton RR, Danielson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. UNI-MED-Verlag, 2005. Bremen, Germany; 2008.
47.
go back to reference Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Michael Felker G, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA [Internet]. 2017 [cited 2022 Jul 13];317(19):1958–66. Available from: https://pubmed.ncbi.nlm.nih.gov/28510680/. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Michael Felker G, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA [Internet]. 2017 [cited 2022 Jul 13];317(19):1958–66. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​28510680/​.
48.
49.
go back to reference Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol [Internet]. 2012 [cited 2022 Jul 19];157(1):80–5. Available from: https://pubmed.ncbi.nlm.nih.gov/21190739/. Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol [Internet]. 2012 [cited 2022 Jul 19];157(1):80–5. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​21190739/​.
50.
go back to reference Nielsen P, Kongi R, Buggisch P, Fischer R. Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate. Arzneimittelforschung [Internet]. 2005 [cited 2022 Jul 19];55(7):376–81. Available from: https://pubmed.ncbi.nlm.nih.gov/16080276/. Nielsen P, Kongi R, Buggisch P, Fischer R. Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate. Arzneimittelforschung [Internet]. 2005 [cited 2022 Jul 19];55(7):376–81. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​16080276/​.
51.
go back to reference Karavidas A, Troganis E, Lazaros G, Balta D, Karavidas IN, Polyzogopoulou E, et al. Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study. Eur J Heart Fail [Internet]. 2021 [cited 2022 Jul 21];23(4):593–7. Available from: https://doi.org/10.1002/ejhf.2092. Karavidas A, Troganis E, Lazaros G, Balta D, Karavidas IN, Polyzogopoulou E, et al. Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study. Eur J Heart Fail [Internet]. 2021 [cited 2022 Jul 21];23(4):593–7. Available from: https://​doi.​org/​10.​1002/​ejhf.​2092.
52.
go back to reference Beck-Da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, De Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol [Internet]. 2013 [cited 2022 Jul 21];168(4):3439–42. Available from: https://pubmed.ncbi.nlm.nih.gov/23680589/. Beck-Da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, De Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol [Internet]. 2013 [cited 2022 Jul 21];168(4):3439–42. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​23680589/​.
54.
go back to reference Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther [Internet]. 2005 [cited 2022 Jul 11];22(9):831–8. Available from: https://pubmed.ncbi.nlm.nih.gov/16225492/. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther [Internet]. 2005 [cited 2022 Jul 11];22(9):831–8. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​16225492/​.
57.
go back to reference Garcia-Fernandez N, Echeverria A, Sanchez-Ibarrola A, PÁramo JA, Coma-Canella I. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. Nephrology (Carlton) [Internet]. 2010 [cited 2022 Jul 11];15(2):178–83. Available from: https://pubmed.ncbi.nlm.nih.gov/20470276/. Garcia-Fernandez N, Echeverria A, Sanchez-Ibarrola A, PÁramo JA, Coma-Canella I. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. Nephrology (Carlton) [Internet]. 2010 [cited 2022 Jul 11];15(2):178–83. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​20470276/​.
58.
go back to reference Rangel ÉB, Espósito BP, Carneiro FD, Mallet AC, Matos ACC, Andreoli MCC, et al. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis. Ther Apher Dial [Internet]. 2010 [cited 2022 Jul 11];14(2):186–92. Available from: https://pubmed.ncbi.nlm.nih.gov/20438541/. Rangel ÉB, Espósito BP, Carneiro FD, Mallet AC, Matos ACC, Andreoli MCC, et al. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis. Ther Apher Dial [Internet]. 2010 [cited 2022 Jul 11];14(2):186–92. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​20438541/​.
60.
go back to reference Toblli JE, Cao G, Angerosa M. The induction of oxidative/nitrosative stress, inflammation, and apoptosis by a ferric carboxymaltose copy compared to iron sucrose in a non-clinical model. J Clin Diagn Res [Internet]. 2015 [cited 2022 Jul 11];9(12):FF08-FF12. Available from: https://pubmed.ncbi.nlm.nih.gov/26816915/. Toblli JE, Cao G, Angerosa M. The induction of oxidative/nitrosative stress, inflammation, and apoptosis by a ferric carboxymaltose copy compared to iron sucrose in a non-clinical model. J Clin Diagn Res [Internet]. 2015 [cited 2022 Jul 11];9(12):FF08-FF12. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​26816915/​.
61.
go back to reference Kassianides X, Gordon A, Sturmey R, Bhandari S. The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study. Kidney Res Clin Pract [Internet]. 2021 [cited 2022 Jul 11];40(1):89–98. Available from: https://pubmed.ncbi.nlm.nih.gov/33745264/. Kassianides X, Gordon A, Sturmey R, Bhandari S. The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study. Kidney Res Clin Pract [Internet]. 2021 [cited 2022 Jul 11];40(1):89–98. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​33745264/​.
62.
go back to reference Rooyakkers TM, Stroes ESG, Kooistra MP, Van Faassen EE, Hider RC, Rabelink TJ, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest [Internet]. 2002 [cited 2022 Jul 24];32 Suppl 1(Suppl. 1):9–16. Available from: https://pubmed.ncbi.nlm.nih.gov/11886426/. Rooyakkers TM, Stroes ESG, Kooistra MP, Van Faassen EE, Hider RC, Rabelink TJ, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest [Internet]. 2002 [cited 2022 Jul 24];32 Suppl 1(Suppl. 1):9–16. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​11886426/​.
64.
go back to reference McMurray JJV, Parfrey PS, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Vol. 2, Kidney International Supplements. Nature Publishing Group. 2012. McMurray JJV, Parfrey PS, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Vol. 2, Kidney International Supplements. Nature Publishing Group. 2012.
65.
go back to reference Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol [Internet]. 2008 [cited 2022 Jul 24];51(2):103–12. Available from: https://pubmed.ncbi.nlm.nih.gov/18191732/. Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol [Internet]. 2008 [cited 2022 Jul 24];51(2):103–12. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​18191732/​.
66.
go back to reference Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol [Internet]. 2007 [cited 2022 Jul 24];50(17):1657–65. Available from: https://pubmed.ncbi.nlm.nih.gov/17950147/. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol [Internet]. 2007 [cited 2022 Jul 24];50(17):1657–65. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​17950147/​.
68.
go back to reference Núñez J, Miñana G, Cardells I, Palau P, Llàcer P, Fácila L, et al. Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the Myocardial-IRON Trial. J Am Heart Assoc [Internet]. 2020 [cited 2022 Jul 13];9(4). Available from: https://pubmed.ncbi.nlm.nih.gov/32067585/. Núñez J, Miñana G, Cardells I, Palau P, Llàcer P, Fácila L, et al. Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the Myocardial-IRON Trial. J Am Heart Assoc [Internet]. 2020 [cited 2022 Jul 13];9(4). Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​32067585/​.
69.
go back to reference Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J [Internet]. 2015 Mar [cited 2022 Jul 13];36(11):657–68. Available from: https://pubmed.ncbi.nlm.nih.gov/25176939/. Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J [Internet]. 2015 Mar [cited 2022 Jul 13];36(11):657–68. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​25176939/​.
70.
go back to reference Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation [Internet]. 2017 [cited 2022 Jul 13];136(15):1374–83. Available from: https://pubmed.ncbi.nlm.nih.gov/28701470/. Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation [Internet]. 2017 [cited 2022 Jul 13];136(15):1374–83. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​28701470/​.
71.
go back to reference •• Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet (London, England) [Internet]. 2020 [cited 2022 Jul 13];396(10266):1895–904. Available from: https://pubmed.ncbi.nlm.nih.gov/33197395/. The AFFIRM-AHF trial, like other trials before it, confirmed that treatment with IV FCM in patients with ID and HF had reduced risk of HF hospitalisation, but in particular, for those who were stabilised after an acute heart failure episode. •• Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet (London, England) [Internet]. 2020 [cited 2022 Jul 13];396(10266):1895–904. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​33197395/​. The AFFIRM-AHF trial, like other trials before it, confirmed that treatment with IV FCM in patients with ID and HF had reduced risk of HF hospitalisation, but in particular, for those who were stabilised after an acute heart failure episode.
72.
go back to reference •• Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet [Internet]. 2022 [cited 2022 Nov 26];0(0). Available from: http://www.thelancet.com/article/S0140673622020839/fulltext. The IRONMAN trial showed that treatment with IV iron in patients with HF reduced LVEF and ID; there was lower risk of heart failure hospital admissions and cardiovascular death (p = 0.07). •• Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet [Internet]. 2022 [cited 2022 Nov 26];0(0). Available from: http://​www.​thelancet.​com/​article/​S014067362202083​9/​fulltext. The IRONMAN trial showed that treatment with IV iron in patients with HF reduced LVEF and ID; there was lower risk of heart failure hospital admissions and cardiovascular death (p = 0.07).
73.
go back to reference Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, et al. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ Heart Fail [Internet]. 2021 [cited 2022 Oct 16];14(5):E008100. Available from: https://pubmed.ncbi.nlm.nih.gov/34003690/. Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, et al. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ Heart Fail [Internet]. 2021 [cited 2022 Oct 16];14(5):E008100. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​34003690/​.
77.
go back to reference Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J [Internet]. 2021 [cited 2022 Jul 13];42(31):3011–20. Available from: https://pubmed.ncbi.nlm.nih.gov/34080008/. Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J [Internet]. 2021 [cited 2022 Jul 13];42(31):3011–20. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​34080008/​.
79.
go back to reference Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail [Internet]. 2016 [cited 2022 Jul 13];18(7):786–95. Available from: https://pubmed.ncbi.nlm.nih.gov/26821594/. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail [Internet]. 2016 [cited 2022 Jul 13];18(7):786–95. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​26821594/​.
80.
go back to reference Martens P, Dupont M, Dauw J, Somers F, Herbots L, Timmermans P, et al. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy. ESC Hear Fail [Internet]. 2019 [cited 2022 Jul 24];6(6):1208–15. Available from: https://pubmed.ncbi.nlm.nih.gov/31562751/. Martens P, Dupont M, Dauw J, Somers F, Herbots L, Timmermans P, et al. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy. ESC Hear Fail [Internet]. 2019 [cited 2022 Jul 24];6(6):1208–15. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​31562751/​.
81.
go back to reference Lacour P, Dang PL, Morris DA, Parwani AS, Doehner W, Schuessler F, et al. The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT study. ESC Hear Fail [Internet]. 2020 [cited 2022 Jul 24];7(3). Available from: https://pubmed.ncbi.nlm.nih.gov/32189474/. Lacour P, Dang PL, Morris DA, Parwani AS, Doehner W, Schuessler F, et al. The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT study. ESC Hear Fail [Internet]. 2020 [cited 2022 Jul 24];7(3). Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​32189474/​.
82.
go back to reference Martens P, Dupont M, Dauw J, Nijst P, Herbots L, Dendale P, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial. Eur Heart J [Internet]. 2021 [cited 2022 Jul 13];42(48):4905–14. Available from: https://pubmed.ncbi.nlm.nih.gov/34185066/. Martens P, Dupont M, Dauw J, Nijst P, Herbots L, Dendale P, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial. Eur Heart J [Internet]. 2021 [cited 2022 Jul 13];42(48):4905–14. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​34185066/​.
83.
go back to reference Martens P, Dupont M, Dauw J, Nijst P, Bertrand PB, Tang WHW, et al. The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial. Eur J Heart Fail [Internet]. 2022 [cited 2022 Jul 13];24(6). Available from: https://pubmed.ncbi.nlm.nih.gov/35303390/. Martens P, Dupont M, Dauw J, Nijst P, Bertrand PB, Tang WHW, et al. The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial. Eur J Heart Fail [Internet]. 2022 [cited 2022 Jul 13];24(6). Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​35303390/​.
84.
go back to reference López-Vilella R, Lozano-Edo S, Arenas Martín P, Jover-Pastor P, Ezzitouny M, Sorolla Romero J, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Hear Fail [Internet]. 2022 [cited 2022 Jul 13];9(1):133–45. Available from: https://pubmed.ncbi.nlm.nih.gov/34964300/. López-Vilella R, Lozano-Edo S, Arenas Martín P, Jover-Pastor P, Ezzitouny M, Sorolla Romero J, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Hear Fail [Internet]. 2022 [cited 2022 Jul 13];9(1):133–45. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​34964300/​.
86.
go back to reference Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail [Internet]. 2018 [cited 2022 Jul 12];20(9):1257–66. Available from: https://pubmed.ncbi.nlm.nih.gov/29917301/. Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail [Internet]. 2018 [cited 2022 Jul 12];20(9):1257–66. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​29917301/​.
87.
go back to reference Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2022 [cited 2022 Nov 26];145(18):E895–1032. https://doi.org/10.1161/CIR.0000000000001063. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2022 [cited 2022 Nov 26];145(18):E895–1032. https://​doi.​org/​10.​1161/​CIR.​0000000000001063​.
88.
Metadata
Title
Treatment of Iron Deficiency in Heart Failure
Authors
Aamir Shamsi
Antonio Cannata
Susan Piper
Daniel I. Bromage
Theresa A. McDonagh
Publication date
17-06-2023
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 7/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01889-4

Other articles of this Issue 7/2023

Current Cardiology Reports 7/2023 Go to the issue

Psychological Aspects of Cardiovascular Diseases (IM Kronish, Section Editor)

Alexithymia and Hypertension: Does Personality Matter? A Systematic Review and Meta-analysis

Regenerative Medicine (SM Wu, Section Editor)

Regulation of Cardiomyocyte Division During Cardiac Regeneration

Myocardial Disease (A Abbate and M Merlo, Section Editors)

The role of microRNA in myocarditis

Regenerative Medicine (SM Wu, Section Editor)

Emerging Signaling Regulation of Sinoatrial Node Dysfunction